Brokerage firm Credit Suisse Downgrades its rating on Dr.Reddy's Laboratories Ltd (ADR)(NYSE:RDY). The shares have been rated Underweight. Previously, the analysts had a Neutral rating on the shares. The rating by Credit Suisse was issued on Jul 26, 2016.
In a different note, Goldman Sachs said it Initiates Coverage on Dr.Reddy's Laboratories Ltd (ADR), according to a research note issued on May 2, 2016. The shares have been rated ‘Neutral’ by the firm.
Dr.Reddy's Laboratories Ltd (ADR) (RDY) made into the market gainers list on Fridays trading session with the shares advancing 0.09% or 0.04 points. Due to strong positive momentum, the stock ended at $43.65, which is also near the day’s high of $43.85. The stock began the session at $43.55 and the volume stood at 2,94,650 shares. The 52-week high of the shares is $68 and the 52 week low is $40.675. The company has a current market capitalization of $7,447 M and it has 17,06,07,650 shares in outstanding.
Dr.Reddy's Laboratories Ltd (ADR)(RDY) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2017 and Q1.Earnings per share were $0.11.
Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics Pharmaceutical Services and Active Ingredients (PSAI) and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company’s business of manufacturing and marketing active pharmaceutical ingredients and intermediates also known as API or bulk drugs. Proprietary Products segment consists of its differentiated formulations business its new chemical entities (NCEs) business and its dermatology focused specialty business operated through Promius Pharma.